Cilengitide Inhibits Neovascularization in a Rabbit Abdominal Aortic Plaque Model by Impairing the VEGF Signaling

Abstract

Background. Cilengitide is a selective αvβ3 and αvβ5 integrin inhibitor. We sought to investigate the effect of cilengitide on the neovascularization of abdominal aortic plaques in rabbits and explore its underlying antiangiogenic mechanism on human umbilical vein endothelial cells (HUVECs). Materials and Methods. For the in vivo experiment, the abdominal aortic plaque model of rabbits was established and injected with different doses of cilengitide or saline for 14 consecutive days. Conventional ultrasound (CUS) and contrast-enhanced ultrasound (CEUS) were applied to measure the vascular structure and blood flow parameters. CD31 immunofluorescence staining was performed for examining neovascularization. Relative expressions of vascular endothelial growth factor (VEGF) and integrin of the plaque were determined. For in vitro experiments, HUVECs were tested for proliferation, migration, apoptosis, and tube formation in the presence of different doses of cilengitide. Relative expressions of VEGF, integrin, and Ras/ERK/AKT signaling pathways were determined for the exploration of underlying mechanism. Results. CEUS showed modestly increased size and eccentricity index (EI) of plaques in the control group. Different degrees of reduced size and EI of plaques were observed in two cilengitide treatment groups. The expressions of VEGF and integrin in the plaque were inhibited after 14 days of cilengitide treatment. The neovascularization and apoptosis of the abdominal aorta were also significantly alleviated by cilengitide treatment. For in vitro experiments, cilengitide treatment was found to inhibit the proliferation, migration, and tube formation of HUVECs. However, cilengitide did not induce the apoptosis of HUVECs. A higher dose of cilengitide inhibited the mRNA expression of VEGF-A, β3, and β5, but not αV. Lastly, cilengitide treatment significantly inhibited the Ras/ERK/AKT pathway in the HUVECs. Conclusions. This study showed that cilengitide effectively inhibited the growth of plaque size by inhibiting the angiogenesis of the abdominal aortic plaques and blocking the VEGF-mediated angiogenic effect on HUVECs.

Cilengitide inhibits osteoclast adhesion through blocking the αvβ3-mediated FAK/Src signaling pathway

“…Cilengitide, an arginine-glycine-aspartic acid (RGD) peptide that targets integrins, can selectively inhibit integrin subunit oligomerization, including alpha v, beta3 (α v β 3 ) and beta5 (α v β 5 ) [ 17 , 18 ]. Previous studies have demonstrated that cilengitide inhibited angiogenesis and induced endothelial cell apoptosis via the inhibition of integrins and the extracellular matrix [ 17 , 19 ]. Moreover, cilengitide has also been demonstrated to have antitumor activity by blocking integrin function [ 20 , 21 ].…”

MEK inhibitors: a promising targeted therapy for cardiovascular disease

“…In atherosclerosis, activated ERK signaling stimulates the secretion of the proangiogenic factor VEGFA, promoting angiogenic activity in the atheromatous lesion ( 87 – 89 ). Active angiogenesis within atherosclerotic plaques is harmful, contributing to intraplaque hemorrhage, plaque expansion, destabilization, and rupture ( 90 , 91 ).…”